BACKGROUND AND PURPOSE: Positive inotropic responses (PIR) to 5-hydroxytryptamine (5-HT) are induced in the left ventricle (LV) in rats with congestive heart failure (CHF); this is associated with upregulation of the G(s)-coupled 5-HT(4) receptor. We investigated whether chronic 5-HT(4) receptor blockade improved cardiac function in CHF rats. EXPERIMENTAL APPROACH: Rats were given either the 5-HT(4) antagonist SB207266 (0.5 mg kg(-1) 24h(-1); MI(int)) or placebo (MI(pl)) through mini-osmotic pumps for 6 weeks subsequent to induction of post-infarction CHF. In vivo cardiac function and ex vivo responses to isoprenaline or 5-HT were evaluated using echocardiography and isolated LV papillary muscles, respectively. mRNA levels were investigated using real-time quantitative RT-PCR. KEY RESULTS: LV diastolic function improved, with 4.6% lower LV diastolic diameter and 24.2% lower mitral flow deceleration in MI(int) compared to MI(pl). SB207266 reduced LV systolic diameter by 6.1%, heart weight by 10.2% and lung weight by 13.1%. The changes in posterior wall thickening and shortening velocity, cardiac output, LV systolic pressure and (dP/dt)(max), parameters of LV systolic function, did not reach statistical significance. The PIR to isoprenaline (10 microM) increased by 36% and the response to 5-HT (10 microM) decreased by 57% in MI(int) compared to MI(pl). mRNA levels for ANP, 5-HT(4(b)) and 5-HT(2A) receptors, MHCbeta, and the MHCbeta/MHCalpha -ratio were not significantly changed in MI(int) compared to MI(pl). CONCLUSIONS AND IMPLICATIONS: Treatment with SB207266 to some extent improved in vivo cardiac function and ex vivo myocardial function, suggesting a possible beneficial effect of treatment with a 5-HT(4) receptor antagonist in CHF.
BACKGROUND AND PURPOSE: Positive inotropic responses (PIR) to 5-hydroxytryptamine (5-HT) are induced in the left ventricle (LV) in rats with congestive heart failure (CHF); this is associated with upregulation of the G(s)-coupled 5-HT(4) receptor. We investigated whether chronic 5-HT(4) receptor blockade improved cardiac function in CHFrats. EXPERIMENTAL APPROACH: Rats were given either the 5-HT(4) antagonist SB207266 (0.5 mg kg(-1) 24h(-1); MI(int)) or placebo (MI(pl)) through mini-osmotic pumps for 6 weeks subsequent to induction of post-infarction CHF. In vivo cardiac function and ex vivo responses to isoprenaline or 5-HT were evaluated using echocardiography and isolated LV papillary muscles, respectively. mRNA levels were investigated using real-time quantitative RT-PCR. KEY RESULTS: LV diastolic function improved, with 4.6% lower LV diastolic diameter and 24.2% lower mitral flow deceleration in MI(int) compared to MI(pl). SB207266 reduced LV systolic diameter by 6.1%, heart weight by 10.2% and lung weight by 13.1%. The changes in posterior wall thickening and shortening velocity, cardiac output, LV systolic pressure and (dP/dt)(max), parameters of LV systolic function, did not reach statistical significance. The PIR to isoprenaline (10 microM) increased by 36% and the response to 5-HT (10 microM) decreased by 57% in MI(int) compared to MI(pl). mRNA levels for ANP, 5-HT(4(b)) and 5-HT(2A) receptors, MHCbeta, and the MHCbeta/MHCalpha -ratio were not significantly changed in MI(int) compared to MI(pl). CONCLUSIONS AND IMPLICATIONS: Treatment with SB207266 to some extent improved in vivo cardiac function and ex vivo myocardial function, suggesting a possible beneficial effect of treatment with a 5-HT(4) receptor antagonist in CHF.
Authors: Brian D Lowes; Edward M Gilbert; William T Abraham; Wayne A Minobe; Patti Larrabee; Debra Ferguson; Eugene E Wolfel; JoAnn Lindenfeld; Tatiana Tsvetkova; Alastair D Robertson; Robert A Quaife; Michael R Bristow Journal: N Engl J Med Date: 2002-05-02 Impact factor: 91.245
Authors: Y Ishikawa; S Sorota; K Kiuchi; R P Shannon; K Komamura; S Katsushika; D E Vatner; S F Vatner; C J Homcy Journal: J Clin Invest Date: 1994-05 Impact factor: 14.808
Authors: E Omerovic; E Bollano; R Mobini; B Madhu; V Kujacic; B Soussi; A Hjalmarson ; F Waagstein Journal: Biochem Biophys Res Commun Date: 2001-02-23 Impact factor: 3.575
Authors: I Sjaastad; I Schiander; A Sjetnan; E Qvigstad; J Bøkenes; D Sandnes; J-B Osnes; O M Sejersted; T Skomedal Journal: Acta Physiol Scand Date: 2003-04
Authors: Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-01-15 Impact factor: 3.000
Authors: F Afzal; K W Andressen; H K Mørk; J M Aronsen; I Sjaastad; C P Dahl; T Skomedal; F O Levy; J-B Osnes; E Qvigstad Journal: Br J Pharmacol Date: 2008-09-01 Impact factor: 8.739
Authors: Trond Brattelid; Eirik Qvigstad; Lise R Moltzau; Silje V S Bekkevold; Dagny L Sandnes; Jon Arne K Birkeland; Tor Skomedal; Jan-Bjørn Osnes; Ivar Sjaastad; Finn Olav Levy Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Faraz Afzal; Eirik Qvigstad; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2011-09-08 Impact factor: 3.000